1Department of Biochemistry, Faculty of Science
2Prince Fahd Bin Sultan Research Chair, Department of Medical Lab Technology, Faculty of Applied Medical Sciences, University of Tabuk
3Department of Endocrinology, King Salman Armed Forces Hospital, Tabuk
4King Fahad Specialist Hospital, Tabuk, Kingdom of Saudi Arabia
*Corresponding Author: Dr. Imadeldin Elfaki PhD, Assistant Professor, Tel: (00966) (014) 4562663, Email: ielfaki@ut.edu.sa
Online published on 21 February, 2019.
It has been reported that in GLUT2 polymorphism (rs8192675) CC homozygotes exhibit a greater absolute HbA1c reduction than T-allele homozygotes upon metformin treatment.
A case control study was performed on 100 T2D patients and 100 healthy controls (HC) collected from Tabuk region. The SLC2A2 gene polymorphism (rs8192675) was investigated by using mutation specific allele specific PCR.
A significant difference was observed in genotype distribution between T2D patients and HC (p<0.03). The frequencies of all 3 genotypes CC, CT, TT reported in T2D patients were 03%, 75% and 22% and in HC were 6%, 58% and 36% respectively. Moreover, our result indicates that a higher percentage of heterozygosity (75%) in cases than in HC (58%). Increased risk of developing T2D in Saudi patients was found to be associated with SCL2A2-CT variant OR 2.11(1.12–3.97) RR 1.42(1.07–1.88) P=0.020, for SCL2A2-CT+ CC variant OR 1.99(1.6–7.2) RR 1.37(1.05–1.80) P=0.030. Therefore, it is indicated that more than 2.11 and 1.99 fold increased risk to T2D was associated with CT+CC and CT genotype of SCL2A2 gene variants.
These findings suggest that SLC2A2 (rs8192675) gene variation is associated with an increased susceptibility to T2D in an ethnic population of Saudi Arabia. However, these findings still need to be confirmed in larger sample size Studies.
Glucose transporter gene, SLC2A2, Type 2 Diabetes mellitus (T2D)
